The Chinese CRDMO credited last year’s growth, in part, to the utilization of existing and newly expanded capacities including the ramp-up of manufacturing sites in Europe.
The certification permits the company to manufacture and release both clinical and commercial sterile drug products from its facility in Saint-Beauzire, France.
